title: Peptic ulcer occurrence in follow-up of chronic gastritis in patients with treated and not eradicated CagA-positive Helicobacter pylori infection.
abstract: The aim of the present prospective investigation was to study 49 dyspeptic Helicobacter pylori (HP)-positive (HP+) or -negative (HP), CagA+ and CagA- patients with a normal pattern or pure chronic gastritis at initial histology as well as normal features or hyperemic gastropathy at initial endoscopy in a two-year follow up. All the HP+ patients were treated with omeprazole 20 mg twice a day plus amoxicillin 1 g twice a day for two weeks. No substantial change was seen in gastritis in CagA+ patients in whom the infection was not eradicated, and, in contrast, a progressive improvement in 13/14 successfully treated patients was found. At endoscopy, a progressive change to a normal picture was seen in 8 and no change in 6 of 14 patients whose HP infection was eradicated, in contrast a worsening in the 9 HP+ patients who were still infected was observed. In particular, peptic lesions arose in 6 of 21 CagA+ patients in whom the infection was not eradicated. In conclusions, the lack of change in chronic gastritis at histology and the progressive worsening of endoscopic hyperemic gastropathy (with peptic lesions arising in 28,6%) when HP+ CagA+ infection is not eradicated, unlike the progressive improvement of the anatomoclinical condition in the patients whose infection was eradicated, draws attention to the relevance of eradicating HP in CagA+ patients even when no peptic lesion is found at initial endoscopy.
authors.affiliation: Microbiology Institute, Second University of Naples, Italy.
authors.forename: R
authors.initials: R
authors.lastname: Carratù
authors.forename: D
authors.initials: D
authors.lastname: Iuliano
authors.forename: M R
authors.initials: MR
authors.lastname: Iovene
authors.forename: F
authors.initials: F
authors.lastname: Ferraraccio
authors.forename: P
authors.initials: P
authors.lastname: Esposito
authors.forename: M I
authors.initials: MI
authors.lastname: Russo
authors.forename: F
authors.initials: F
authors.lastname: Montella
authors.forename: G
authors.initials: G
authors.lastname: Abbate
authors.forename: M A
authors.initials: MA
authors.lastname: Tufano
mesh_terms: D000328:Adult; D000368:Aged; D000658:Amoxicillin / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D000942:Antigens, Bacterial; D001426:Bacterial Proteins / Q000032:analysis*; D002908:Chronic Disease; D004942:Esophagitis, Peptic / Q000209:etiology*; D005260:Female; D005500:Follow-Up Studies; D005756:Gastritis / Q000150:complications*; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000627:therapeutic use; D010406:Penicillins / Q000627:therapeutic use; D011446:Prospective Studies; D016896:Treatment Outcome
chemical_list: D000897:Anti-Ulcer Agents; D000942:Antigens, Bacterial; D001426:Bacterial Proteins; D010406:Penicillins; C080866:cagA protein, Helicobacter pylori; D000658:Amoxicillin; D009853:Omeprazole